Coronary Artery Disease
Conditions
Keywords
coronary bifurcation, coronary stent
Brief summary
The Axxess™ Biolimus A9™ Eluting Coronary Bifurcation Stent System (AXXESS System; Biosensors, International, Morges, Switzerland) is a dedicated bifurcation stent, designed to cover the lesion at the level of the carina. Although deemed ideal for lesions involving only the proximal MV (1,0,0 according to Medina classification ref), this device may be used also in more complex bifurcation lesions when additional DES are required in the distal MV and/or in the SB. In the present registry the investigators report the performance and the efficacy of the self-expanding biolimus-eluting AxxessTM stent for the treatment of bifurcation lesions in a real-world population.
Detailed description
Despite a comprehensive understanding of the physiological and technical issues regarding the coronary bifurcations lesions, percutaneous coronary intervention (PCI) in this setting remains challenging. When compared with non-bifurcation lesions, treatment of bifurcation lesions is associated with increased adverse clinical events and inferior angiographic outcomes including procedural complications. This is due to several technical challenges, including both anatomical (proximal-to-distal vessel mismatch \[tapering\], angulation and calcification) and procedural (plaque shift, and side-branch \[SB\] closure) features. Current balloon-expandable drug-eluting stent (DES) have not been designed to treat the bifurcation lesions; in particular, the inability of DES to adequately scaffold and preserve the ostium of SB represents a the major reason of failure, because this is the most common site for restenosis. Recently a large variety of dedicated bifurcation stents have been developed in order to 1) provide an easier access to the SB and to scaffold more effectively its ostium, and 2) adapt to main vassel (MV) tapering, and to the bifurcation anatomy.
Interventions
DEVICEAXXESS stent
Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
Sponsors
Clinica Mediterranea
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. significant (≥70% diameter stenosis) bifurcation lesion; 2. MV reference diameter between 2.75 and 4.75 mm by visually estimated 3. SB reference diameter ≥2.25 mm by visual estimate; 4. bifurcation angle (between the distal MV and the SB) \<70° by visual estimate
Exclusion criteria
1. patients with contraindications to prolonged dual-antiplatelet therapy, 2. known sensitivity to limus compounds, stainless steel, titanium, or nickel; 3. inclusion in others studies on bifurcation lesions; and 4. all bifurcation lesions not satisfying the angiographic inclusion criteria reported above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| device success | intraprocedural | successful deployment of the AxxessTM stent into the target lesion, without system failure or device-related complication. |
Outcome results
None listed